| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
49,450,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$26.32 - $47.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 623 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
119,323 |
119,323 |
201,796 |
329,048 |
| Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,836,738 |
$14,896,079 |
| Total People Sold |
1 |
1 |
15 |
17 |
| Total Sell Transactions |
3 |
3 |
36 |
63 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pace Gary W |
Director |
– • – |
2024-03-08 |
4 |
S |
$30.60 |
$2,754,000 |
D/D |
(90,000) |
22,127 |
|
14% |
|
| Pace Gary W |
Director |
– • – |
2024-03-07 |
4 |
S |
$30.81 |
$870,598 |
D/D |
(28,257) |
112,127 |
|
12% |
|
| Pace Gary W |
Director |
– • – |
2024-03-06 |
4 |
S |
$29.67 |
$31,628 |
D/D |
(1,066) |
140,384 |
|
11% |
|
| Gaugler Daryl |
Chief Operating Officer |
• – – |
2024-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
33,700 |
65,494 |
|
- |
|
| Dunker Kristen Marie |
Chief Administrative Officer |
• – – |
2024-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
33,700 |
59,075 |
|
- |
|
| Lee Frank D. |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
99,520 |
99,520 |
|
- |
|
| Riker Lauren Bullaro |
Senior Vice President, Finance |
• – – |
2024-01-02 |
4 |
D |
$32.00 |
$5,088 |
D/D |
(159) |
22,528 |
|
- |
|
| Slonin Jonathan |
Chief Medical Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
51,196 |
|
- |
|
| Slonin Jonathan |
Chief Medical OfficerOfficer |
• – – |
2023-12-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,884 |
|
-3% |
|
| Winston Roy |
Chief Medical Officer |
• – – |
2023-08-02 |
4 |
S |
$34.88 |
$17,751 |
D/D |
(509) |
52,440 |
|
24% |
|
| Riker Lauren Bullaro |
Senior Vice President, Finance |
• – – |
2023-07-05 |
4 |
AS |
$38.91 |
$25,019 |
D/D |
(643) |
22,687 |
|
-27% |
|
| Dunker Kristen Marie |
Chief Administrative Officer |
• – – |
2023-06-14 |
4 |
AS |
$37.03 |
$239,473 |
D/D |
(6,467) |
25,375 |
|
-28% |
|
| Dunker Kristen Marie |
Chief Administrative Officer |
• – – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,950 |
31,842 |
|
- |
|
| Pace Gary W |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
141,450 |
|
- |
|
| Reinhart Charles A. Iii |
Chief Financial Officer |
• – – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
42,626 |
|
- |
|
| Christie Christopher |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
5,261 |
|
- |
|
| Riker Lauren Bullaro |
Senior Vice President, Finance |
• – – |
2023-06-14 |
4 |
AS |
$37.47 |
$244,606 |
D/D |
(6,366) |
22,687 |
|
-28% |
|
| Riker Lauren Bullaro |
Senior Vice President, Finance |
• – – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
29,053 |
|
- |
|
| Brege Laura |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
11,322 |
|
- |
|
| Winston Roy |
Chief Medical Officer |
• – – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,950 |
52,306 |
|
- |
|
| Kronenfeld Mark A. |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
19,672 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
8,374 |
|
- |
|
| Gaugler Daryl |
Chief Operating Officer |
• – – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
31,539 |
|
- |
|
| Froimson Mark |
Director |
– • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
7,843 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
186,481 |
|
- |
|
781 Records found
|
|
Page 1 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.34 (1.28%) 
